Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:18 PM
Ignite Modification Date:
2026-03-26 @ 3:18 PM
NCT ID:
NCT07362758
Eligibility Criteria:
Inclusion Criteria:
* 1\. Age range of 14-70 years old (including threshold), gender not limited;
* 2\. KPS score\>60 points, life expectancy greater than 6 months;
* 3\. Male and female patients of appropriate age must use reliable methods of contraception before entering the trial, during the research process until 30 days after discontinuation of medication; Reliable contraceptive methods will be determined by the primary researchers or designated personnel;
* 4\. Those who can understand this experiment and have signed the informed consent form.
* 5\. Before screening (at baseline), corresponding conditions should be met;
* 6\. Indications for severe, recurrent, or refractory immune related diseases, including immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), systemic lupus erythematosus（SLE），systemic sclerosis （SSc） etc., meet the corresponding inclusion criteria; For other types of diseases, researchers will assess whether they meet the inclusion requirements after fully evaluating the risks and benefits based on the patient's treatment needs.
Exclusion Criteria:
* 1\) Study participants who are allergic or hypersensitive to any component of the investigational drug, including those who are allergic to messenger RNA (mRNA) vaccines or other RNA LNP products.
* 2\) Merge any active infections that require antibiotic treatment and have not been controlled for at least one week prior to D1 administration.
* 3\) Malignant tumors diagnosed within the first 2 years of screening are excluded, except for skin basal cell carcinoma, squamous cell carcinoma, or cervical cancer in situ that has been adequately treated.
* 4\) Uncontrolled ischemic heart disease, including unstable angina within the previous 6 months of screening, or evidence of active ischemic heart disease on electrocardiogram.
* 5\) New York Heart Association (NYHA) grade III-IV heart failure.
* 6\) Study participants with combined active hepatitis B virus (HBV) infection \[defined as surface antigen (HBsAg) positive and HBV DNA positive (detected by PCR)\].
* 7\) Study participants with combined active hepatitis C virus (HCV) infection (defined as HCV RNA positive (detected by PCR), regardless of anti HCV antibody status).
* 8\) Human immunodeficiency virus (HIV) infection or history of HIV infection.
* 9\) Study participants who tested positive for Treponema pallidum specific antibodies.
* 10\) There may be active infection of Mycobacterium tuberculosis.
* 11\) Women who are currently pregnant, breastfeeding, or planning to become pregnant.
* 12\) Combining severe or recently (\<2 months) diagnosed medical conditions, as determined by the researchers, may affect the study participants' tolerance to the study drug or their ability to complete the study process.
* 13\) Received attenuated live vaccine or protein subunit vaccine within 30 days prior to the first study medication.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
14 Years
Maximum Age:
70 Years
Study:
NCT07362758
Study Brief:
Protocol Section:
NCT07362758